Open-label phase 2 RCT in 18 patients with homozygous familial hypercholesterolaemia on lipid-lowering therapy: zodasiran 200 mg or 300 mg reduced fasting LDL cholesterol by a mean 35.7% and 39.9% at month 6, with no drug-related severe adverse events.
RCTn = 18
Raal et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial